Tebipenem pivoxil

Drug Profile

Tebipenem pivoxil

Alternative Names: L-084; ME1211; Orapenem; SPR-994

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth K.K.
  • Developer Meiji Seika Pharma; Spero Therapeutics
  • Class Antibacterials; Carbapenems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilus infections; Streptococcal infections
  • Phase I/II Urinary tract infections

Most Recent Events

  • 20 Oct 2017 Spero Therapeutics plans to initiate a pivotal phase III trial in patients with complicated urinary tract infections in second half of 2018
  • 20 Oct 2017 Spero Therapeutics initiates a phase I trial for Urinary tract infections (In volunteers) in USA
  • 10 Oct 2017 Tebipenem pivoxil sub-licensed to Spero Therapeutics worldwide (excluding Japan and other undisclosed Asian countries)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top